Discussion
Admilparant, an experimental oral therapy being developed by Bristol Myers Squibb, slowed lung function declines among people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The study, ALOFT-IPF (NCT06003426), enrolled approximately 1,255 adults with IPF ages 40 and older. The trial was open to…